Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | LPO | P22079 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15531306 | 0.78 | TLR8 (0.42) | KMT2AALDH1A1POLBTLR8LPO | |
| SCHEMBL18038297 | 0.75 | KMT2A (0.42) | KMT2AALDH1A1POLBTLR8CYP19A1 | |
| SCHEMBL6767037 | 0.74 | ALDH1A1 (0.45) | KMT2AALDH1A1POLBTLR8CYP1A2 | |
| SCHEMBL3065697 | 0.73 | ALDH1A1 (0.40) | KMT2AALDH1A1POLBTLR8CYP19A1 | |
| SCHEMBL3171671 | 0.72 | CYP1A2 (0.32) | KMT2AALDH1A1POLBCYP19A1CYP1A2 | |
| SCHEMBL18038278 | 0.71 | ALDH1A1 (0.32) | KMT2AALDH1A1POLBTLR8CYP19A1 | |
| SCHEMBL7972375 | 0.71 | KDM4E (0.33) | KMT2AALDH1A1POLBTLR8HTT | |
| SCHEMBL6767033 | 0.71 | ALDH1A1 (0.32) | KMT2AALDH1A1POLBTLR8 | |
| SCHEMBL18007731 | 0.70 | KMT2A (0.35) | KMT2AALDH1A1POLBHTTMEN1 | |
| Pentane SCHEMBL19922685 | 0.69 | ALDH1A1 (0.62) | KMT2AALDH1A1POLBTLR8LPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2025002491-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | MASARYKOVA UNIVERZITA (CZ) | 2025-01-02 | — | — | WO | disclosed |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| EP-0934311-A2 | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES | BAYER AG (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0850924-A1 | Aromatic diselenides and selenosulphides for use as antioxidant agents | OXIS Isle of Man, Limited (GB) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998016507-A2 | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-04-23 | — | — | WO | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| US-5656754-A | REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0623622-A1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0343277-B1 | A process for the production of 3-hydrocarbyl-3-cephems | BRISTOL MYERS SQUIBB CO (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0343277-A1 | A process for the production of 3-hydrocarbyl-3-cephems | Bristol-Myers Squibb Company (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4857539-A | Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents | STERLING DRUG INC. (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | KMT2A 4677/4885ALDH1A1 1674/4885POLB 480/4885 |
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | KMT2A 752/4885ALDH1A1 1654/4885POLB 3001/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | KMT2A 4633/4885ALDH1A1 996/4885POLB 4161/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | KMT2A 1927/4885ALDH1A1 215/4885POLB 3365/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | KMT2A 1011/4885ALDH1A1 800/4885POLB 364/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | KMT2A 4677/4885ALDH1A1 1674/4885POLB 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.